Review Article

Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper

Esther Redondo, Irene Rivero-Calle, Enrique Mascarós, Daniel Ocaña, Isabel Jimeno, Ángel Gil, Manuel Linares, María Ángeles Onieva-García, Fernando González-Romo, José Yuste, Federico Martinón-Torres

Abstract

Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in adults, particularly older adults and those with underlying medical conditions. Vaccination has emerged as a potential key strategy to prevent RSV-related morbidity and mortality. This NeumoExperts Prevention (NEP) Group scientific paper aims to provide an evidence-based positioning and RSV vaccination recommendations for adult patients. We review the current literature on RSV burden and vaccine development and availability, emphasizing the importance of vaccination in the adult population. According to our interpretation of the data, RSV vaccines should be part of the adult immunisation programme, and an age-based strategy should be preferred over targeting high-risk groups. The effectiveness and efficiency of this practice will depend on the duration of protection and the need for annual or more spaced doses. Our recommendations should help healthcare professionals formulate guidelines and implement effective vaccination programmes for adult patients at risk of RSV infection now that specific vaccines are available.

© 2024 The Authors. Published by Elsevier España, S.L.U. on behalf of SEPAR. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
and prophylaxis positioning of available products to prevent and control RSV infections. This paper aims to offer evidence-based recommendations for the vaccination of adult patients against RSV.

Methods

A comprehensive literature review was conducted using electronic databases, including PubMed, Embase, and Cochrane Library until December 2023, to identify relevant studies, clinical trials, and guidelines for RSV infection and vaccination in adults. The search terms included "respiratory syncytial virus", "adults", "vaccine", and related keywords. The selected articles were critically appraised, and data were synthesised to develop evidence-based recommendations.

Epidemiology and Clinical Manifestations

RSV Epidemiology in Adults

RSV has long been recognised as a leading cause of respiratory tract infections in infants and young children. However, recent research has also shed light on the significant burden of RSV infections in adults. Based on data from the Global Burden of Disease report, which covers 204 countries and territories, the mortality rate for individuals aged 70 years and older in 2019 exceeded that of other age groups. It is worth noting that the mortality rate for people aged 70 years and older compared to infants under 5 years old increased from 0.57 in 1990 to 1.85 in 2019. Understanding the epidemiology of RSV in adults is crucial to identifying high-risk populations and implementing effective preventive measures, such as vaccination.

RSV peaks are typically observed during the fall and winter, but inter-seasonal RSV activity exists, and its reservoir is exclusively human. Occupational exposure is a crucial factor in the epidemiology of RSV in adults. Healthcare and daycare workers are at a higher risk of contracting RSV due to their frequent contact with infected individuals. These occupations play a critical role in the transmission dynamics of RSV, as infected healthcare workers can spread the virus within healthcare settings and vulnerable patient populations.

Adults aged 60 years and older, especially those residing in long-term care facilities or nursing homes, are at increased risk of severe RSV-related illness. A recent meta-analysis found that in adults aged 60 years and older, the attack rate for RSV-associated acute respiratory infection was estimated at 1.62%; the hospitalisation attack rate was 0.15%, and the in-hospital case fatality rate (hCFR) was 7.13%. In Spain, Hepe-Montero et al. estimated an hCFR of 7.91% for patients aged 60 years or older.

Additionally, age-related comorbidities, such as chronic obstructive pulmonary disease (COPD), congestive heart failure, stroke, chronic kidney disease and diabetes, further heighten the risk of severe RSV infections and the need for hospitalisation. Furthermore, individuals with compromised immune systems, such as those undergoing immunosuppressive therapy, solid organ transplant recipients, people with HIV infection, and especially those with haematologic malignancies undergoing chemotherapy, are at an elevated risk of severe RSV infections.

The chronic use of inhaled corticosteroids has also been associated with the increased risk of RSV pneumonia (aOR 2.08 [95% CI: 1.39–3.09]). These individuals often experience more prolonged and severe illness and are at an increased risk of complications, including hospitalisation and death.

Complications include bacterial co-infection in up to 29% of adults hospitalised for RSV pneumonia, the most common pathogens being Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus. This co-infection rate is even higher than in influenza patients, estimated to occur in 20% of patients. RSV infection may also be complicated by cardiovascular events, including acute coronary syndrome, worsening congestive heart failure and arrhythmias in 14–22%. Finally, acute functional loss has been associated with a significant short- and long-term reduction in quality of life, which may last for months.

In sum, RSV infections in adults represent a significant public health concern and have a substantial impact on morbidity, mortality, and healthcare utilisation. Older adults, individuals with chronic medical conditions, immunocompromised individuals, and those with occupational exposure face an elevated risk of severe RSV-related illness.

Adult RSV Clinical Manifestations

RSV infection in adults can present with a wide spectrum of clinical manifestations, ranging from mild respiratory symptoms to severe lower respiratory tract infections. Individual risk factors, comorbidities, and immunological status influence the clinical presentation of RSV in adults. The most common clinical symptoms of RSV infection in adults include cough, rhinorrhea (runny nose), sore throat, nasal congestion, and fever. These symptoms often resemble those of other respiratory viral infections, so clinical diagnosis is challenging without laboratory confirmation. RSV infection may be mistaken for a common cold or influenza, especially during seasonal peaks of respiratory viral activity.

While RSV infections in adults can be self-limiting and resolve without complications, they can also progress to more severe respiratory illnesses, including pneumonia, as a complication of RSV infection that may require hospitalisation. In some individuals, particularly those with underlying chronic respiratory conditions, RSV infection can lead to exacerbations of pre-existing conditions, such as COPD or asthma. In severe cases, RSV infection may result in lower respiratory tract infections, such as bronchiolitis and pneumonia. Bronchiolitis is more commonly observed in infants and young children but can also occur in adults, especially those with compromised lung function or immunocompromised status. RSV is also a cause of pneumonia in 49.3% of patients with confirmed RSV infection, primarily in the form of consolidations (23.8%) or ground-glass opacities (19.9%).

RSV infections in the elderly are frequent and more severe than those with influenza A/B, especially in vulnerable populations, and can result in hospitalisation and, in rare cases, lead to fatal outcomes. These severe outcomes are more likely in individuals with multiple risk factors, advanced age, and significant comorbidities.

In summary, RSV infection in adults has different presentations, ranging from asymptomatic or mild respiratory symptoms to exacerbations of underlying chronic conditions and severe lower respiratory tract infections, such as bronchiolitis and pneumonia. Clinical manifestations can vary widely, and individual risk factors and comorbidities influence the severity of illness. Early identification through efficient diagnostic testing, suitable treatment and specific preventive measures like vaccination are essential in reducing the morbidity and mortality linked to RSV infection in adults.

The Virus and Its Diagnosis

RSV is a negative-sense, non-segmented RNA virus of more than 15,000 nucleotides. Unlike influenza viruses, it cannot reassort segments, so a large-scale pandemic is unlikely. RSV has two major specific antigenic subgroups (A and B) that differ in a number of proteins, but the major genetic diversity lies within the attachment glycoprotein G. However, glycoprotein F is highly conserved between RSVA and RSVB, making it an ideal candidate as a vaccine.
antigen, once stabilised in its “pre-fusion” structural conformation, which induces more potent neutralising antibodies by presenting more important epitopes.43,44

Clinical features in adults are not sufficiently helpful in distinguishing RSV from other respiratory agents; therefore, laboratory confirmation may be required. Molecular testing, such as polymerase chain reaction (PCR)-based assays, are rapid, highly sensitive and specific, making them the preferred tool in hospitalised adult patients, particularly when using lower respiratory tract samples. The preferred sample for detecting RSV in adults is a nasopharyngeal swab, but adding additional samples such as saliva, sputum, and serology increases diagnosis accuracy by 2.6-fold.45 Multiplex PCR-based assays enable the simultaneous detection of several respiratory pathogens, albeit at a higher cost. Rapid antigen detection tests (RADTs) provide a quicker, cheaper and more useful point-of-care diagnostic tool, although their sensitivity is less than 10% compared to serological tests and PCR. Immunochromatographic assays targeting RSV F-glycoprotein are used for most RADTS.46 Viral culture is time-consuming and demands trained staff, limiting it to reference labs. Serology offers limited value for immediate diagnosis or patient care, yet when paired with PCR in acute and convalescent phases, its sensitivity is heightened beyond that of viral culture. Whole-genome sequencing and next-generation sequencing techniques are presently unavailable for clinical purposes. These techniques are intended mostly for public health research due to their capacity for detecting evolutionary diversity and potential transmission patterns.47

RSV Older Adult Vaccination: Current Status

Vaccine Development for RSV

Historically, the development of an RSV vaccine has been challenging.48 In light of recent advances in understanding the biology and structure of the RSV virus, particularly the importance of the pre-fusion configuration of the F antigen (Pre-F Ag).49 numerous vaccine candidates have been developed and tested. Each candidate uses a distinct but all use Pre-F Ag. Here, we discuss the current status of RSV vaccine development for the elderly population and highlight key characteristics of various vaccine candidates (Table 1).

Subunit Vaccines

Subunit vaccines are either protein- or particle-based. Protein-based vaccines employ purified RSV antigens, including the F or G protein, often formulated with adjuvants to enhance the immune response. Two vaccines have successfully completed Phase 3 trials and have recently been approved for use in older adults (Tables 2 and 3).40,41 The first one, a prefusion F protein RSV vaccine (RSVPreF3, Arexvy, GSK), reported efficacy results in Phase 3 clinical trial in adults ≥ 60 years (AResV1 006 Study) of 82.6% (95% CI: 57.9–94.1%) for RSV-associated lower respiratory tract disease (LRTD), and 94.1% (95% CI: 62.4–99.9%) for severe RSV-associated LRTD.42 Further analyses stratified by season revealed that one dose of the RSVPreF3 vaccine in preventing symptomatic, laboratory-confirmed RSV-associated LRTD was 82.6% (96.95% CI: 57.9–94.1%) during the first RSV season and 56.1% (95% CI: 28.2–74.4%) during the second full season (Table 3). The cumulative efficacy of a single dose over the two combined seasons was 74.5% (97.5% CI: 60.0–84.5%) in preventing RSV-associated LRTD and 77.5% (95% CI: 57.9–89.0%) in preventing medically attended RSV-associated LRTD. In addition, the vaccine was well tolerated, with no safety concerns.43,44

The second one, a bivalent RSV-A and RSV-B stabilised prefusion F protein vaccine (RSVpref, Abxysvo, Pfizer) reported efficacy results in Phase 3 clinical trial in adults ≥ 60 years (RENOIR study) of 66.7% (96.66% CI: 28.8–85.8%) for RSV lower respiratory tract illness (LRTI) with at least two signs or symptoms and 85.7% (96.66% CI: 32.0–98.7%) for most severe respiratory disease defined by the presence of three or more symptoms associated with RSV (Table 2).45 Analyses by season reported that one dose of the RSV pref vaccine prevented symptomatic, laboratory-confirmed RSV-associated LRTD with 88.9% efficacy (95% CI: 53.6–98.7%) during the first RSV season and 78.6% (95% CI: 23.2–96.1%) during the partial second season (Table 3). The efficacy of a single dose over the two combined seasons was 84.4% (95% CI: 59.6–95.2%) in preventing RSV-associated LRTD and 81.0% (95% CI: 43.5–95.2%) in preventing medically attended RSV-associated LRTD. In addition, the vaccine was well tolerated, with no safety concerns.46,47 Nanoparticle-based vaccines use self-assembling nanoparticles presenting key RSV antigens, such as the F glycoprotein or the RSV prefusion-stabilised F protein. They aim to induce a robust neutralising antibody response and have shown promising results in preclinical and early clinical studies.48 IVX-A12, a bivalent vaccine candidate based on nanoparticle technology for treating older adults with RSV and human metapneumovirus (hMPV), started its Phase 3 clinical trial in older adults in June 2023.49

Live Attenuated Vaccines

Live attenuated vaccines (LAV) mimic natural infection to induce a strong immune response.50,51 RSV-MiniL4–0 (modified parainfluenza gene), a codon-pair optimised LAV, has shown a humoral and cellular immune response similar to wild-type infection in non-human primates and has completed Phase 1 trials.52

Chimeric Vaccines

Chimeric live virus vaccine candidates express RSV proteins in related attenuated viruses with favourable safety profiles. Unlike vector vaccine candidates, chimeric vaccines show favourable antigen presentation that activates an adaptive immune response. CPI-RSV-F (BLB201), currently in Phase 1 trials, is a chimeric RSV vaccine candidate that includes older adults. Based on an attenuated strain of canine parainfluenza virus expressing the RSV-F protein, a Phase 1 trial is ongoing in the elderly population. The first study cohort showed that 64% of subjects had serum anti-RSV antibody responses above baseline levels.53

Messenger Ribonucleic Acid (mRNA) Vaccines

mRNA vaccines have revolutionised vaccine development, exemplified by their successful application in COVID-19 vaccines.54,55 Moderna’s mRNA-1345, an mRNA candidate encoding stabilised RSV pre-F protein, recently reported efficacy results in Phase II + III trial clinical trial in adults ≥ 60 years of 83.7% (95.88% CI: 66.1–92.2%; p < 0.0001) against RSV LRTD as defined by two or more symptoms and 82.4% (96.36% CI: 34.8–95.3) against the disease with at least three signs or symptoms.56 In addition, vaccine efficacy was 68.4% (95% CI, 50.9–79.7) against RSV-associated acute respiratory disease. In general, the vaccine was well tolerated, with no safety concerns. Supported by these results, the company requested the market approval of mRNA-1345 in July 2023.

Recombinant Vector Vaccines

Recombinant vector vaccines use a genetically modified, replication-deficient virus as a vehicle to elicit both humoral and cellular immune responses by delivering genes encoding specific RSV antigens. Two candidates in clinical development in the elderly population were discontinued due to strategic decisions (Ad26.RSV.preF)57 or failure to meet one of the primary endpoints (MVA-BN-RSV).58
Table 1
Summary of Vaccine Candidates in Development for Older Adults Categorised by Design Strategy.11

<table>
<thead>
<tr>
<th>Type of vaccine</th>
<th>Candidate vaccine / sponsor</th>
<th>Antigen</th>
<th>Adjuvant</th>
<th>Mechanism of action</th>
<th>Phase 1 trial (no. participants)</th>
<th>Phase 2 trial (no. participants)</th>
<th>Phase 3 trial (no. participants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subunit vaccine</td>
<td>VN-02000</td>
<td>Daiichi Sankyo Immunovaccine</td>
<td>VAGA-9001a</td>
<td>MAB1-9002b</td>
<td>Protein-based</td>
<td>NCT04914520 (48)</td>
<td>NCT02472548 (40)</td>
</tr>
<tr>
<td></td>
<td>DPX-RSV</td>
<td>GSK</td>
<td>ShHe</td>
<td>DepoVax aluminium hydroxide</td>
<td>Protein-based: SHe generates a non-neutralising Ab and CD4+ T-cell response</td>
<td>NCT04851977 and ACTRN12618-000948291 (60)</td>
<td>NCT04681833 (120)</td>
</tr>
<tr>
<td></td>
<td>BARS13</td>
<td>Pfizer</td>
<td>PreF</td>
<td>None or cyclosorpin A</td>
<td>Protein-based: RSV G; immunosuppressing</td>
<td>NCT04090658, NCT03814590, and NCT04657198 (1055)</td>
<td>NCT04090658 (1235)</td>
</tr>
<tr>
<td></td>
<td>RSVPreF</td>
<td>Pfizer</td>
<td>PreF</td>
<td>None or aluminium hydroxide</td>
<td>Protein-based: Induce immune response with stabilised preF</td>
<td>NCT04675198 (1055)</td>
<td>NCT03529773 (1235)</td>
</tr>
<tr>
<td></td>
<td>121</td>
<td>Pfizer</td>
<td>Stabilised Pre-F DS-Cav1</td>
<td>None or aluminium hydroxide</td>
<td>Particle-based: Presentation of D5-Cav1 on computationally designed VLP generates a neutralising Ab response against preF</td>
<td>2020-003633-38 (90)</td>
<td>NCT055903183 (264)</td>
</tr>
<tr>
<td></td>
<td>IVX-121</td>
<td>Icosavaxx</td>
<td>RSV-F/hMPV-F</td>
<td>MF59</td>
<td>Protein-based: mRNA encodes for a stabilised preF glycoprotein eliciting neutralising antibodies</td>
<td>NCT05664334, 120</td>
<td>NCT05127434 (100 healthy adults, 300 older adults, 180 women, and 40 children)</td>
</tr>
<tr>
<td></td>
<td>IVX-A12</td>
<td>Icosavaxx</td>
<td>mRNA-1345</td>
<td>Moderna</td>
<td>mRNA encodes for a stabilised preF glycoprotein eliciting neutralising antibodies</td>
<td>NCT04528719 (100)</td>
<td>NCT05127434 (100 healthy adults, 300 older adults, 180 women, and 40 children)</td>
</tr>
<tr>
<td></td>
<td>RSV-ML40</td>
<td>Codagenix</td>
<td>mRNA LNP</td>
<td>Sanofi</td>
<td>mRNA encodes for a stabilised preF glycoprotein eliciting neutralising antibodies</td>
<td>NCT04528719 (100)</td>
<td>NCT05127434 (100 healthy adults, 300 older adults, 180 women, and 40 children)</td>
</tr>
<tr>
<td></td>
<td>RSV-Min40</td>
<td>Codagenix</td>
<td>All viral proteins</td>
<td>None</td>
<td>Protein-based: L. altered for attenuation</td>
<td>NCT04295070 (36)</td>
<td>NCT04295070 (36)</td>
</tr>
<tr>
<td></td>
<td>Chimeric</td>
<td>CPI-RSV-F</td>
<td>PreF</td>
<td>None</td>
<td>Protein-based: Parainfluenza virus type 5-vectored live attenuated RSV vaccine</td>
<td>NCT05281263 (30)</td>
<td>NCT05281263 (30)</td>
</tr>
<tr>
<td></td>
<td>BARS13</td>
<td>Chimeric</td>
<td>G Model</td>
<td>Protein-based</td>
<td>NCT04886596 (25,000)</td>
<td>NCT04732871 (1720)</td>
<td>NCT04886596 (40,000)</td>
</tr>
<tr>
<td></td>
<td>RSVPreF</td>
<td>Chimeric</td>
<td>Redondo</td>
<td>Protein-based</td>
<td>NCT03814590 (1235)</td>
<td>NCT04785612 (62)</td>
<td>NCT04032093 (1153)</td>
</tr>
<tr>
<td></td>
<td>121</td>
<td>Chimeric</td>
<td>Sankyo</td>
<td>Protein-based</td>
<td>NCT04071158 (713)</td>
<td>NCT04071158 (713)</td>
<td>NCT05035212 (30,000)</td>
</tr>
<tr>
<td></td>
<td>IVX-121</td>
<td>Chimeric</td>
<td>Sankyo</td>
<td>Protein-based</td>
<td>NCT04071158 (713)</td>
<td>NCT04071158 (713)</td>
<td>NCT05035212 (30,000)</td>
</tr>
<tr>
<td></td>
<td>IVX-A12</td>
<td>Chimeric</td>
<td>mRNA-1345</td>
<td>Moderna</td>
<td>mRNA encodes for a stabilised preF glycoprotein eliciting neutralising antibodies</td>
<td>NCT04071158 (713)</td>
<td>NCT04071158 (713)</td>
</tr>
<tr>
<td></td>
<td>RSV-ML40</td>
<td>Chimeric</td>
<td>mRNA LNP</td>
<td>Sanofi</td>
<td>mRNA encodes for a stabilised preF glycoprotein eliciting neutralising antibodies</td>
<td>NCT04071158 (713)</td>
<td>NCT04071158 (713)</td>
</tr>
<tr>
<td></td>
<td>RSV-Min40</td>
<td>Chimeric</td>
<td>All viral proteins</td>
<td>None</td>
<td>Protein-based: L. altered for attenuation</td>
<td>NCT04295070 (36)</td>
<td>NCT04295070 (36)</td>
</tr>
</tbody>
</table>


Positioning and Recommendations for Vaccination in Older Adult Patients

The rationale for the recommendations to use RSV vaccines in older adults is based on the known burden of the disease and the evidence of moderate to high efficacy in preventing symptomatic RSV-associated LRTD.22,23 It is important to note that the trials had limited enrollment of individuals at highest risk for RSV disease, and that protection duration and eventual need for additional doses have not yet been established. From an individual protection perspective, healthcare providers should consider individual risk factors, patient preferences, and vaccine characteristics when deciding whether to vaccinate. Post-marketing surveillance and additional studies will provide further information on the safety and effectiveness of RSV vaccines in older adults, which will guide future recommendations.24

Target Population for RSV Vaccination

Age-based Indication Strategy

The age-based indication strategy involves recommending RSV vaccination for all individuals within a specific age range, regardless of their individual risk levels or underlying conditions. This approach does not require identifying and targeting specific high-risk groups, making it a convenient and efficient strategy. The decision on the age threshold should balance the greatest impact on disease burden and its efficiency.25
Table 2
Efficacy of Currently Licensed RSV Vaccines for Adults 60 Years or Older Based on Phase 3 Trial Results.52,55

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>n/N, Vaccinated group</th>
<th>n/N, placebo group</th>
<th>Vaccine efficacy (CI), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSVpreF3 protein vaccine (GSK)52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RSV acute respiratory illness: ≥ 2 respiratory symptoms/signs for ≥ 24h OR ≥ 1 respiratory symptom/sign not systemic for ≥ 24h</td>
<td>27/12,466</td>
<td>95/12,494</td>
<td>71.7 (56.2–82.3)</td>
</tr>
<tr>
<td>RSV LRTD: ≥ 2 lower respiratory symptoms/signs for ≥ 24h including ≥ 1 lower respiratory sign or ≥ 3 lower respiratory symptoms for ≥ 24h</td>
<td>7/12,466</td>
<td>40/12,494</td>
<td>82.6 (57.9–94.1)</td>
</tr>
<tr>
<td>RSV LRTD with ≥ 2 lower respiratory signs or assessed as ‘severe’ by the investigator</td>
<td>1/12,466</td>
<td>17/12,494</td>
<td>94.1 (62.4–99.9)</td>
</tr>
<tr>
<td>Bivalent RSV prefusion F vaccine (Pfizer)53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RSV LRTI: ≥ 1 respiratory symptom lasting more than 1 day</td>
<td>22/16,306</td>
<td>58/16,308</td>
<td>62.1 (37.1–77.9)</td>
</tr>
<tr>
<td>RSV LRTI: ≥ 2 symptoms: ≥ 2 lower respiratory signs/symptoms lasting more than 1 day</td>
<td>11/16,306</td>
<td>33/16,308</td>
<td>66.7 (28.8–85.8)</td>
</tr>
<tr>
<td>RSV LRTI: ≥ 3 symptoms: ≥ 3 lower respiratory signs/symptoms lasting more than 1 day</td>
<td>2/16,306</td>
<td>14/16,308</td>
<td>85.7 (37.9–98.4)</td>
</tr>
</tbody>
</table>

* 96.66% of confidence interval. CI: confidence interval; LRTD: lower respiratory tract disease; LRTI: lower respiratory tract illness; n: number of events; N: number of participants; RSV: respiratory syncytial virus.

Table 3
Efficacy of One Dose of Currently Licensed RSV Vaccines for Adults Aged ≥ 60 Years During the First RSV Season, the Second RSV Season and Both Seasons, 2021–2023.53,54

<table>
<thead>
<tr>
<th>Efficacy evaluation period</th>
<th>Vaccine efficacy against outcome52</th>
<th>Vaccine efficacy against outcome52</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSVpreF3 protein vaccine (GSK)52</td>
<td>RSV-associated LRTD²</td>
<td>RSV-associated medically attended LRTD³</td>
</tr>
<tr>
<td>Season 1</td>
<td>82.6 (57.9–94.1)</td>
<td>87.5 (58.9–97.6)</td>
</tr>
<tr>
<td>Season 2 (full)</td>
<td>56.1 (28.2–74.4)</td>
<td>77.5 (57.9–89.0)</td>
</tr>
<tr>
<td>Combined seasons 1 and 2 (interim)</td>
<td>74.6 (62.1–83.5)</td>
<td></td>
</tr>
<tr>
<td>Bivalent RSVpreF vaccine (Pfizer)53</td>
<td>RSV-associated LRTD</td>
<td>RSV-associated medically attended LRTD</td>
</tr>
<tr>
<td>Season 1c</td>
<td>88.9 (53.6–98.7)</td>
<td>84.5 (32.0–98.3)</td>
</tr>
<tr>
<td>Season 2 (interim)</td>
<td>78.6 (23.2–96.1)</td>
<td></td>
</tr>
<tr>
<td>Combined seasons 1 and 2 (interim)</td>
<td>84.4 (59.6–95.2)</td>
<td>81.0 (43.5–95.2)</td>
</tr>
</tbody>
</table>

CI: confidence interval; LRTD: lower respiratory tract disease; LRTI: lower respiratory tract illness; RSV: respiratory syncytial virus.

* For RSVpreF3 (GSK), LRTD was defined as two or more lower respiratory symptoms (new or increased sputum, cough, and dyspnoea) or signs (new or increased wheezing, crackles or rhonchi detected during chest auscultation, respiratory rate ≥ 20 respirations per minute, low or decreased oxygen saturation (<95% or ≤ 90% if baseline was >95%, and need for oxygen supplementation) for ≥ 24h, including one or more lower respiratory signs, or three or more lower respiratory symptoms for ≥ 24h. For RSVpreF (Pfizer) estimates, LRTD refers to the RSVpreF trial endpoint of RSV LRTI with three or more lower respiratory signs or symptoms (see Table 2).

2 Medically attended RSV-associated LRTD defined as LRTD plus attention at one or more inpatient or outpatient health care services. Estimates were not included in per-protocol assessments.

3 Season 1 vaccine efficacy estimates reflect efficacy against first events occurring during the first complete RSV season for Northern Hemisphere participants, partial first RSV season for Southern Hemisphere participants for GSK (May 2021–April 2022; exact study-defined season dates were site-dependent) and complete RSV season Southern Hemisphere participants for Pfizer (August 2021–October 2022; exact study-defined season dates were site-dependent).

4 Season 2 vaccine efficacy estimates (GSK) reflect efficacy against first events occurring during the second complete Northern Hemisphere RSV season for Northern Hemisphere participants (August 2022–March 2023; exact study-defined season dates were site-dependent). In addition to Northern Hemisphere participants, Southern Hemisphere participants were also included in these analyses, but this time span reflects an intersession period with low RSV incidence in the Southern Hemisphere.

5 Season 2 (interim) vaccine efficacy estimates (Pfizer) reflect efficacy against first events occurring during the second complete RSV season for Northern Hemisphere participants only (July 2022–January 2023); Southern Hemisphere data not yet available.

6 Combined season 1 and 2 (interim) vaccine efficacy estimates reflect efficacy against first events occurring any time during Season 1 or Season 2. The mean time from start to end of efficacy surveillance was approximately 15 months (GSK) or 12 months (Pfizer) per participant.

7 Interim analysis underpowered to estimate efficacy.

8 Manufacturer-calculated efficacy. Includes events > 14 days after injection and person-time available from the manufacturer’s pivotal Phase 3 trial.

9 Estimates adjusted for participant age and region.

10 Estimates are unadjusted.

11 Interim analysis underpowered to estimate efficacy.

12 95% CI.

13 96.95% CI; the CI for the primary trial endpoint was adjusted for multiplicity.

14 97.5% CI; the CI for the primary trial endpoint was adjusted for multiplicity.

High-risk Groups Targeting Strategy

The strategy of targeting high-risk groups involves prioritising RSV vaccination for populations at higher risk of severe RSV infection or its complications (Table 4). The main justifications for a strategy of targeting high-risk groups would be: (1) high-risk groups, such as older adults, people with chronic respiratory diseases, immunocompromised individuals and healthcare workers, are more likely to experience severe RSV infection or transmit the virus to vulnerable populations;66,67 (2) limited vaccine supply or higher vaccine costs may necessitate prioritising high-risk groups to achieve the greatest public health impact; and (3) targeting high-risk groups allows for a more targeted approach, ensuring that those most susceptible to severe RSV illness are protected.70

Timing and Scheduling of RSV Vaccination

Timing of RSV Vaccination: Maximising Protection

To ensure maximum protection, it is important to consider the following:

- Seasonal outbreaks: RSV infection typically occurs in seasonal outbreaks, with the highest incidence in temperate regions occurring during the autumn and winter months. However, RSV
activity can vary geographically. Therefore, local surveillance data should be considered when determining the optimal timing of vaccination.

- Ideal timing: Vaccination should ideally be administered before the onset of the RSV season to provide the highest level of protection. However, considering that the currently available vaccines induce protection for at least two seasons, the timing should be as early as possible for those eligible, irrespective of RSV activity.

Schedule of RSV Vaccination: Tailoring to Vaccine Type and Individual Factors

- Vaccine type: The schedule may vary depending on the specific vaccine. This includes the number of doses required and the interval between doses. Both currently approved RSV vaccines are recommended for administration as a single dose.
- Booster doses: Evidence to determine the need for revaccination is not currently available.

Integrating RSV Vaccination With Other Vaccines: Optimising Immunisation Coverage

- Recommended timing and schedules: RSV vaccination in adults can be seamlessly integrated into routine immunisation schedules by considering the recommended timing and schedules of other vaccines. This allows for efficient and convenient administration of multiple vaccines.
- Co-administration with other vaccines: By combining vaccines, individuals can receive multiple vaccinations during a single healthcare visit, reducing the need for additional appointments and associated costs. Both RSVpreF (Arexvy, GSK) and RSVpreF (Abrxvyso, Pfizer) can be administered concurrently with the seasonal influenza vaccine. RSVpreF shows non-inferior immune responses in adults aged 60 and older, but co-administration resulted in numerically lower RSV A and B neutralising titres and influenza A and B hemagglutination inhibition titres, with unknown clinical relevance. RSVpreF, studied in adults aged 65 and older, also demonstrated non-inferior immune responses, but co-administration with adjuvanted influenza vaccine showed similar reductions. RSVpreF requires a two-week interval before tetanus, diphtheria, and acellular pertussis vaccine, and is associated with lower immune responses to pertussis components in co-administration; the clinical relevance remains unknown.

Despite the lack of specific studies, public health authorities can decide to authorise the co-administration of RSV with other vaccines, favouring the opportunity of vaccination against the eventual immunological interference.

NEP Positioning and RSV Prophylaxis Recommendations in Adults

The Spanish Neumoexperts Prevention Group (NEP; www.neumoexpertos.org) publishes updated immunisation recommendations to prevent community-acquired pneumonia in adults. The proposed vaccine schedule prioritises individual protection to effectively prevent CAP in adults. This schedule is designed to assist healthcare professionals in daily practice by offering the most optimal vaccination recommendations based on the latest evidence. Fig. 1 illustrates the most recent NEP recommendations, including those for RSV vaccination.

Concerning RSV prevention, NEP recommends the following measures:

1. Implement infection control measures in healthcare facilities and long-term care settings.
2. Promote public awareness and education regarding RSV transmission and preventive measures.
3. Develop and reinforce surveillance systems to monitor community RSV activity and promptly identify outbreaks.
4. Recommendations for vaccination.

From an individual protection perspective, the NEP in Spain recommends RSV vaccination for older adults aged ≥ 60, especially those with chronic pulmonary disease, chronic cardiovascular disease, and other diagnoses or conditions that cause impaired lung function or poor cough strength and stagnation of secretions (extreme obesity or neurological impairments), kidney disease, diabetes, immunosuppression, or institutionalised status. Although there are currently two approved vaccines for adults, RSVpreF (Arexvyso, Pfizer) and RSVpreF3 (Arexvy, GSK) that are difficult to compare, given their different clinical studies, varying case definitions, and analysis criteria, both vaccines have demonstrated their efficacy and safety and are recommended in this age group.

From a public health perspective, we believe that an aged-based indication is the most recommendable strategy, although the concrete age threshold should be determined balancing the burden of disease prevented and the associated costs of the intervention. The Centres for Disease Control and Prevention (CDC) recommends RSV vaccination for individuals aged ≥ 60 based on shared clinical decision-making between the healthcare provider and the vaccine (Table 5) using either available vaccine. In the United Kingdom, the Joint Committee on Vaccination and Immunisation (JCVI) used their modelling to establish the indication for RSV vaccination among older adults aged ≥ 75 (Table 5).

Irrespective of the age indication, any adult aged over 60 years with specific risk factors for severe RSV disease (Table 4) should be prioritised for vaccination. This strategy likely constitutes a good starting point for any RSV vaccination policy and should be warranted to protect the most vulnerable (Table 6). Also, healthcare workers should be offered RSV vaccination because they are at a higher risk of contracting RSV and to the increased risk of transmitting RSV to their patients.
VACCINATION GUIDE AGAINST COMMUNITY ACQUIRED PNEUMONIA IN ADULTS 2024

**SHOULD BE VACCINATED**
- Adults with immunosuppressive conditions
- Older than 60 years
- Adults with chronic respiratory, cardiovascular, and hepatic pathologies, non-advanced renal disease and diabetes mellitus
- Institutionalised and long-term care facilities
- Down’s Syndrome
- Smoking
- Alcoholism
- Obesity
- Schizophrenia
- Neurological impairment
- Vulnerable population by socioeconomic criteria
- Previous COVID-19 pneumonia
- Previous IPD disease
- CSF fistula
- Asplenia
- Cochlear implant
- At risk or essential professions
- Pregnancy
- Rheumatic or digestive underlying diseases that do not receive immunosuppressive treatment
- Hemoglobinopathies and anemias
- Adults from 18 to 59 years

**ICON GUIDE**
- Adults with immunosuppressive
- Older than 60 years
- Adults with chronic respiratory, cardiovascular, and hepatic pathologies
- Adults with non-advanced renal disease
- Diabetes mellitus
- Institutionalised and long-term care facilities
- Down’s Syndrome
- Smoking
- Alcoholism
- Obesity
- Schizophrenia
- Neurological impairment
- Vulnerable population by socioeconomic criteria
- Previous COVID-19 pneumonia
- Previous IPD disease
- CSF fistula
- Asplenia
- Cochlear implant
- At risk or essential professions
- Pregnancy
- Rheumatic or digestive underlying diseases that do not receive immunosuppressive treatment
- Hemoglobinopathies and anemias
- Adults from 18 to 59 years

**Fig. 1.** Vaccination guide against community-acquired pneumonia in adults caused by vaccine-preventable diseases. CSF: cerebrospinal fluid; IPD: invasive pneumococcal disease.

Adapted from Redondo et al.70

<table>
<thead>
<tr>
<th>Table 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Official Recommendations on the Use of Licensed RSV Vaccines for Older Adults.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Agency/society</th>
<th>Age (years)</th>
<th>Risk groups</th>
<th>Vaccine implementation practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDC (US)74</td>
<td>≥ 60</td>
<td>Pulmonary/Heart Disease, Immunosuppression, Institutionalised Risk groups</td>
<td>Arexvy (GSK) and Abrysvo (Pfizer), Shared Clinical Decision-Making</td>
</tr>
<tr>
<td>JCVI (UK)73</td>
<td>≥ 75</td>
<td>Pulmonary/Heart Disease, Cardiac Disease, Hepatic Insufficiency, Kidney Disease, Diabetes, Immunosuppression, Institutionalised, Neurological Diseases</td>
<td>Arexvy (GSK) and Abrysvo (Pfizer), Vaccination Programme</td>
</tr>
<tr>
<td>NEP (SP)</td>
<td>≥ 60</td>
<td></td>
<td>Arexvy (GSK) and Abrysvo (Pfizer), Individual recommendation ≥ 60 Vaccination Programme: at least risk group</td>
</tr>
</tbody>
</table>

CDC: Centres for Disease Control and Prevention; JCVI: Joint Committee on Vaccination and Immunisation.
Conclusion

Severe RSV disease can have significant consequences in individuals aged >60 years, particularly those with chronic medical conditions or other risk factors. Vaccination effectively reduces the risk of disease, lessens the severity of illness, and protects vulnerable populations. It is imperative for individuals aged >60 years to prioritise their health by considering vaccination against RSV as part of their healthy lifestyle and ideal immunisation schedule against pneumonia. Ongoing research, including studies on new vaccine candidates and antiviral therapies, offers hope for the development of even more effective interventions. As vaccines reach the population, implementing positioning strategies, such as improved infection control measures in healthcare facilities and targeted education campaigns, and promoting preventive measures, such as hand hygiene and respiratory etiquette, can help mitigate the impact of RSV on adult health. However, RSV vaccination constitutes a key pillar in the prevention strategy. Continued research, collaboration between scientists, vaccine manufacturers, healthcare professionals and policymakers, and investment in RSV surveillance systems are indispensable to advance our understanding of RSV epidemiology, risk factors, and clinical outcomes in adults and to develop evidence-based interventions to safeguard this vulnerable population.

Authors’ Contributions

All authors have significantly contributed to the conceptualization and performance of the study. The literature analysis workload has been equally divided among the authors. The elaboration of recommendations has been discussed and agreed among the members, including the multidisciplinary perspective of the NeumExpert group. All authors have contributed to the critical review of the manuscript.

Funding Sources

This work was supported by consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103; FM-T), DIAVIR (Instituto de Salud Carlos III (ISCIII)/DTS19/00049/Cofinanciado FEDER; Proyecto de Desarrollo Tecnológico en Salud), Resvi-Omics (Instituto de Salud Carlos III (ISCIII)/PI19/01039/Cofinanciado FEDER), BI-BACVIR (PRIS-3; Agencia de Conocimiento en Salud (ACS)—Servicio Gallego de Salud (SERGAS)—Xunta de Galicia; Spain), Programa Traslacional COVID-19 (ACS—Servicio Gallego de Salud (SERGAS)—XUNTA de Galicia; Spain) and Axencia Galega de Innovación (GAIN; IN607B 2020/08—XUNTA de Galicia; Spain); and ReSVinetx (Instituto de Salud Carlos III (ISCIII)/PI16/01569/Cofinanciado FEDER), Enterogen (Instituto de Salud Carlos III (ISCIII)/PI19/01090/Cofinanciado FEDER), OMI-COVI-VAC (PI22/00406/Cofinanciado European Regional Development Fund, Grupos de Referencia Competitiva (IINE607A2021/05) and Axencia Galega de Innovación (GAIN; IN845D 2020/23—Xunta de Galicia; Spain).

Conflicts of Interest

FM-T has acted as principal investigator in randomised control trials of Ablynx, Abbot, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, MedImmune, Novavax, Novartis and GSK, with honoraria paid to his institution. FM-T reports a relationship with GSK Vaccines SRL that includes consulting or advisory. FM-T reports a relationship with Pfizer Inc that includes consulting or advisory. FM-T reports a relationship with Sanofi Pasteur Inc that includes consulting or advisory. FM-T reports a relationship with Janssen Pharmaceuticals Inc that includes consulting or advisory. FM-T reports a relationship with Seqirus Pty Ltd that includes consulting or advisory. ER has participated in advisory boards, conferences, courses and lectures organised by Sanofi Pasteur, MSD, GSK, Seqirus, Pfizer and AstraZeneca. IRC has participated in advisory boards organised by MSD, GSK, Sanofi and Pfizer. IRC has been involved in clinica trials funded by Ablynx, Abbot, Seqirus, Sanofi Pasteur MSD, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, MedImmune, Novavax, Novartis and GSK, alt-hough the funds were paid to the institution. EM has participated in advisory boards by Astra-Zeneca, Boehringer Ingelheim, Esteve, GSK, MSD, Menarini, Mundifarma, Novartis, Orion, Pfizer, Roche, Rovi, Takeda and TEVA. DO has participated in advisory boards from Lilly, Boehringer Ingelheim, Novartis, Pfizer, Takeda, Esteve, Almirall, GlaxoSmithKline, Astra-Zeneca, Chiesi, Mundipharma, Teva, Solvay Pharma, Rovi, Gebro Pharma, Janssen, MSD, Novo Nordisk and Menarini. JH has participated in advisory boards from Pfizer, Sanofi Pasteur, and conference attendance scholarships paid by Menarini, Esteve. AG has participated in advisory boards by Pfizer, GlaxoSmithKline, Janssen, MSD and Sanofi Pasteur. ML has participated in advisory boards and research projects organised by Pfizer. FGR has participated in advisory boards, conferences, courses and lectures organised by Sanofi Pasteur, MSD, GSK, Pfizer and Moderna. JY received grants from MSD-USA (Merck Investigator Studies Programme), and Pfizer, outside of this work and the funds were awarded to the Institution. JY participated in advisory boards or-ganized by MSD and Pfizer. The remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors thank Alfonso Trento at Medical Statistic Consulting for medical writing services and editorial support in the preparation of this manuscript.

References


morbidity in adults aged 65 years and older in high-income countries: a system- 
itic literature review and meta-analysis. Influenza Other Respir Viruses. 2021; 

4. Ambrosch A, Luber D, Klavonw F, Kabesch M. Focusing on severe infections 
with the respiratory viral infection (RSV) in adults: risk factors, symptomatology 
and clinical course compared to influenza A/B and the original SARS-CoV-2 strain. 

respiratory viral infection in older adults before and during the COVID-
19 pandemic. JAMA Netw Open. 2023;6:e2250634.

management of acute respiratory infections in older adults: a systematic review 

7. McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar I, Falsey AR. Rates of med-
ically attended RSV among US adults: a systematic review and meta-analysis. 
Open Forum Infect Dis. 2022;9:ofac300.

Evaluating the individual and national burden of disease associated with RSV 

viral surveillance report from the WHO meeting in November 2022. 

tory syncytial virus and influenza virus infection in adult primary care patients:
association of age with prevalence, diagnostic features and illness course. Int J 

parative assessment of reported symptoms of influenza, respiratory syncytial 
virus, and human metapneumovirus infection during hospitalization and post-
discharge assessed by Respiratory Intensity and Impact Questionnaire. Influenza 
Other Respir Viruses. 2022;16:79–89.

the patient experience with respiratory syncytial virus infection: report from 


short- and mid- to long-term mortality in older adults hospitalized with 


17. Taleb SA, Al Thani AA, Al Ansari K, Yassine HM. Human respiratory syncytial 
virus: pathogenesis, immune responses, and current vaccine approaches. Eur 

sis of respiratory viral infections in adults substantially increases when adding 
sputum saliva, and serology testing to nasopharyngeal swab RT-PCR. Infect 

19. Talbot HK, Belongia EA, Walsh EE, Schaffner W. Respiratory viral infection in 

20. Griffiths C, Drows SJ, Marchant DJ. Respiratory viral infection: infection detec-

tory viral disease burden and costs despite prior administration of antigenic 

RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing 
bio.

23. EMA-EPAR. Abrisvo Respiratory syncytial virus vaccine (bivalent, recombiant). 
2023.

24. EMA-EPAR. Arexvy (Recombiant respiratory syncytial virus pre-fusion F pro-

Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J 

viral infection (RSV) in adults [Presentation Slides]. Advisory Committee on 
Immunization Practices meeting; June 21, Atlanta, GA; 2023.

viral infection vaccines in older adults: recommendations of the advisory 
committee on immunization practices – United States, 2023. MMWR 
Recommendations and Reports. 2023;72:843–801.

2023;388:1465–77.

29. Swanson KA, Raino-Toimko JN, Williams ZP, Luna L, Peredeluch M, Kishko 
focuses antibody responses to a conserved neutralization domain. Sci Immunol. 
2023;8(76):eabq466.

30. Icosavax Initiates Phase 2 Trial of IIX-V12 Against RSV and hMPV in Older Adults 

31. Pollard AJ, Bijkher EM. A guide to vaccination: from basic principles to new 

L, et al. Live-attenuated vaccines prevent respiratory viral infection-related 


